Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-04

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer, is associated with cardiovascular events that may impact on the therapeutic decision.

The aim of this registry is to determine if and how cardiovascular co-morbidities impact on the physicians' decision for anticancer treatment in lung cancer patients by comparing it to the European Lung Cancer Working Party (ELCWP) guidelines

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Distress and Quality of Life During the Diagnostic Phase of a Suspected Serious Lung Disease

NCT02060877

Suspected Lung Cancer

COMPLETED

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

NCT06387017

RECRUITING NA

Metabolomics Predict Therapy Response

NCT03736993

NSCLC, Stage IIIA

COMPLETED NA

Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)

NCT01337102

Non Small Cell Lung Cancer

COMPLETED NA

Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma

NCT03156868

Non-small Cell Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Treatment left at the discretion of the participant

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological diagnosis of lung cancer, either NSCLC or SCLC patients and carcinoid tumours
* Untreated lung cancer of any stage and any treatment (including palliative care only).
* Availability for participating in the detailed follow-up of the protocol.
* Signed informed consent.
* Age above 18 years.
* Presence of at least one co-morbidity:
* Any active or past cardiac ischemia
* Reduced left ventricular ejection fraction (\< 50%)
* Obstructive cardiomyopathy
* Valvular dysfunction (3 or 4/4; valvular replacement)
* Arrhythmia (atrial flutter or fibrillation, significant ventricular arrhythmia, 2nd-3rd degree auriculo-ventricular block, Wolf-Parkinson-White and other similar aberrant conduction, bifascicular block, arrhythmogenic right ventricular dysplasia)
* Uncontrolled hypertension (systolic blood pressure (BP) \> 160 millimeter of mercury (mmHg) or diastolic BP \> 100 mmHg on ≥ 1 hypotensive drug) or controlled hypertension on ≥ 2 concurrent hypotensive drugs
* Active or treated peripheral arteritis (grade 2 or more)
* Cerebrovascular events
* Pulmonary embolism and/or thrombophlebitis or patients at high risk of thrombophilia (homozygous Leiden factor…)
* Aortic aneurism

Exclusion Criteria

* Thymoma and thymic malignancies, pleural mesothelioma.
* Patient previously treated for lung cancer.
* Tumours for which complete staging cannot be assessed.
* History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No